Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Nature Chemistry|May 20, 2025
Discovery of acylsulfenic acid-featuring natural product sulfenicin and characterization of its biosynthesisDan Xue, Hongbin Zou, Yanping Qiu, et al.
American Journal of Hematology|January 28, 2022
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trialEvangelos Terpos, Meletios A Dimopoulos, Mario Boccadoro, et al.
The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|March 28, 2025
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic DermatitisYan Zhao, Litao Zhang, Liming Wu, et al.
International Journal of Dermatology|November 22, 2025
Efficacy and Safety of Anti-IL-4Rα Stapokibart in Elderly Patients With Moderate-To-Severe Atopic DermatitisYan Zhao, Litao Zhang, Liming Wu, et al.
Advances in Therapy|July 12, 2025
Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis Treated with Stapokibart over 52 weeks: A Post Hoc Analysis of a Phase 3 TrialYan Zhao, Litao Zhang, Liming Wu, et al.
The Journal of Dermatological Treatment|July 15, 2026
Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trialsYan Zhao, Furen Zhang, Bin Yang, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|July 25, 2025
Efficacy and Safety of Extending Dosing Interval of Stapokibart in Patients with Atopic DermatitisYan Zhao, Cheng Zhou, Xiaoyong Man, et al.
Pageof 4